STOCK TITAN

Veritone (NASDAQ: VERI) launches $50M at-the-market common stock program

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Veritone, Inc. entered into a sales agreement with UBS Securities, Needham & Company, and Craig-Hallum to sell up to $50.0 million of common stock from time to time in an at-the-market equity offering under its existing Form S-3 shelf registration.

The sales agents will use commercially reasonable efforts to execute sales on The Nasdaq Global Market or other trading venues, for a commission of up to 3.0% of the gross sales price, plus reimbursed expenses. Veritone is not obligated to sell any shares, and the agreement can be terminated by either side on ten days’ notice, upon certain adverse events, or by mutual agreement.

Positive

  • None.

Negative

  • None.
Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
ATM program size $50.0 million Maximum aggregate offering price of common stock under sales agreement
Sales agent commission up to 3.0% of gross sales price Compensation rate payable to sales agents on shares sold
Shelf registration effectiveness date June 21, 2024 Form S-3 (File No. 333-280148) effectiveness
Prospectus supplement date May 21, 2026 Date of prospectus supplement governing ATM offering terms
Rule reference Rule 415(a)(4) Defines at-the-market equity offering under the Securities Act
Termination notice period ten days Advance notice required by either party to terminate the agreement
at-the-market equity offering financial
"made by any method permitted that is deemed to be an “at-the-market” equity offering as defined in Rule 415(a)(4)"
An at-the-market equity offering is a way for a public company to raise cash by selling newly issued shares directly into the open market at current market prices over time through a broker. Think of it as gradually selling items on an online marketplace at whatever buyers are paying now rather than holding a single big sale; it gives the company flexible access to funds but can lower each existing owner’s share of the company and put gentle downward pressure on the stock price if done in large amounts.
Form S-3 regulatory
"pursuant to the Company’s registration statement on Form S-3 (File No. 333-280148)"
Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.
prospectus supplement regulatory
"the related prospectus supplement dated May 21, 2026 (the “Prospectus Supplement”)"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
indemnification and contribution regulatory
"the Company has agreed in the Sales Agreement to provide indemnification and contribution to the Sales Agents against certain liabilities"
Rule 415(a)(4) regulatory
"deemed to be an “at-the-market” equity offering as defined in Rule 415(a)(4) promulgated under the Securities Act"
Rule 415(a)(4) is a U.S. Securities and Exchange Commission rule that lets a company add more securities to an already effective shelf registration, so those additional shares or bonds can be sold later without filing a completely new registration. For investors it matters because it gives the issuer the flexibility to raise cash quickly—like having an open credit line—while creating the possibility of dilution or changes in supply that can affect share price.
false 0001615165 0001615165 2026-05-21 2026-05-21
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 21, 2026

 

 

Veritone, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-38093   47-1161641

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

5291 California Avenue, Suite 350  
Irvine, California   92617
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (888) 507-1737

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   VERI   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 1.01

Entry into a Material Definitive Agreement.

On May 21, 2026, Veritone, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with UBS Securities LLC, Needham & Company, LLC and Craig-Hallum Capital Group LLC, as sales agents (collectively, the “Sales Agents”), pursuant to which the Company may offer and sell from time to time, at its option, shares of the Company’s common stock through the Sales Agents. The issuance and sale, if any, of shares of the Company’s common stock under the Sales Agreement will be made pursuant to the Company’s registration statement on Form S-3 (File No. 333-280148), which became effective on June 21, 2024 and the related prospectus supplement dated May 21, 2026 (the “Prospectus Supplement”), in each case filed with the U.S. Securities and Exchange Commission (the “SEC”). In accordance with the terms of the Sales Agreement, under the Prospectus Supplement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million from time to time through the Sales Agents.

The sale, if any, of shares of the Company’s common stock under the Sales Agreement will be made by any method permitted that is deemed to be an “at-the-market” equity offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on The Nasdaq Global Market or any other trading market for the Company’s common stock. Subject to the terms and conditions of the Sales Agreement, the Sales Agents will use their commercially reasonable efforts to sell the shares of the Company’s common stock from time to time, based upon the Company’s instructions.

The compensation payable to the Sales Agents as sales agents shall be up to 3.0% of the gross sales price of the shares sold through the sales agents pursuant to the Sales Agreement. In addition, the Company will reimburse the Sales Agents for certain expenses incurred in connection with the Sales Agreement, and the Company has agreed in the Sales Agreement to provide indemnification and contribution to the Sales Agents against certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended.

The Company is not obligated to sell any shares of common stock under the Sales Agreement. The offering of shares of common stock pursuant to the Sales Agreement will terminate upon (a) the election of the Sales Agents upon the occurrence of certain adverse events, (b) ten days’ advance notice from the Company to the Sales Agents or ten days’ advance notice from any Sales Agent, on behalf of itself, to the Company or (c) otherwise by mutual agreement of the parties pursuant to the terms of the Sales Agreement.

The Sales Agreement is attached to this Current Report on Form 8-K as Exhibit 1.1 and is incorporated herein by reference. The foregoing description of the material terms of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the exhibit attached hereto.

The representations, warranties and covenants contained in the Sales Agreement were made solely for the benefit of the parties to the Sales Agreement, and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Sales Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Sales Agreement and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the SEC.

A copy of the legal opinion of Cooley LLP relating to the shares of common stock being offered pursuant to the Sales Agreement is filed as Exhibit 5.1 to this Current Report on Form 8-K.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the shares of common stock discussed herein, nor shall there be any offer, solicitation, or sale of the shares of common stock in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

 


Item 9.01.

Financial Statements and Exhibits.

 

Exhibit

No.

   Description
1.1    Sales Agreement, by and among Veritone, Inc., UBS Securities LLC, Needham & Company, LLC and Craig-Hallum Capital Group LLC, dated May 21, 2026.
5.1    Opinion of Cooley LLP.
23.1    Consent of Cooley LLP (contained in Exhibit 5.1).
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 21, 2026   VERITONE, INC.
    By:  

/s/ Michael L. Zemetra

      Michael L. Zemetra
     

Executive Vice President, Chief Financial Officer

and Treasurer

FAQ

What did Veritone (VERI) announce regarding new common stock sales?

Veritone entered a sales agreement with UBS Securities, Needham & Company, and Craig-Hallum to sell up to $50.0 million of common stock in an at-the-market equity program under its effective Form S-3 shelf registration and a related May 21, 2026 prospectus supplement.

How will Veritone’s at-the-market offering through VERI stock work?

Veritone may instruct the sales agents to sell common stock from time to time directly on The Nasdaq Global Market or other trading markets. These transactions qualify as an “at-the-market” equity offering under Rule 415(a)(4), allowing flexible, incremental share sales.

What is the maximum amount Veritone (VERI) can raise under this program?

Under the prospectus supplement, Veritone may offer and sell shares of its common stock with an aggregate offering price of up to $50.0 million. Actual proceeds will depend on how many shares the company chooses to sell and the prices obtained.

What fees will Veritone pay the sales agents in this VERI ATM program?

The sales agents are entitled to receive up to 3.0% of the gross sales price of shares sold through them under the agreement. Veritone will also reimburse certain expenses and provide indemnification and contribution against specified liabilities under securities laws.

Is Veritone required to issue shares under this at-the-market facility?

Veritone is not obligated to sell any shares under the sales agreement. The at-the-market facility simply gives the company the option to issue common stock over time, and the program can be terminated by either party on ten days’ notice or upon specified events.

When did Veritone’s shelf registration for this program become effective?

The at-the-market offering is conducted under Veritone’s existing registration statement on Form S-3 (File No. 333-280148), which became effective on June 21, 2024, and a related prospectus supplement dated May 21, 2026 filed with the SEC.

Filing Exhibits & Attachments

5 documents